Pregnancy outcomes when adding a progesterone pessary dose amongst women who are receiving frozen embryo transfer with hormone replacement therapy, compared with placebo.

Phase 4

Withdrawn

• Conditions: Reproductive Health and Childbirth - Fertility including in vitro fertilisation; Infertility

• Registration Number: ACTRN12617001016325
• Lead Sponsor: Monash IVF Pty Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-07-14
• Last Update Posted: 28 October 2019

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Female
• Target Recruitment: 304

Inclusion Criteria

1. Is a female receiving single embryo FET with HRT at Monash IVF
2. Is between the age of 18 and 45 years
3. Has provided informed consent
4. Speaks sufficient English to provide informed consent
5. Has been prescribed an initial progesterone pessary dose of 400mg bd or tds and is obtaining these pessaries from Slade pharmacy
6. Low serum progesterone levels at Day 2 of progesterone treatment (<50nmol/L)

Exclusion Criteria

•Already completed an HRT FET cycle in this study
•Planned double embryo transfer.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ive birth rate<br>[At time of birth]

Secondary Outcome Measures

Name	Time	Method
Clinical pregnancy levels at 16 days of treatment. This will be measured by serum hCG level. [Day 16 of treatment];Serum progesterone levels at Day 2 and Day 16 of treatment[Day 2 and Day 16 of treatment]